Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Ergotamine tartrate [USP:JAN]
RN: 379-79-3
UNII: MRU5XH3B48
InChIKey: CJMJLDQKTOJACI-BGQAIRJTSA-N

Note

  • A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of MIGRAINE DISORDERS.

Molecular Formula

  • C33-H35-N5-O5.1/2C4-H6-O6

Molecular Weight

  • 1313.4244
 

Classification Codes

Classification Codes

  • Analgesic (Specific in Migraine)
  • Drug / Therapeutic Agent
  • Human Data
  • Mutation Data
  • Reproductive Effect

Superlist Classification Code

  • Threshold Planning Quantity (TPQ) = 500/10000 lb

Names and Synonyms

Name of Substance

  • Ergotamine tartrate [USP:JAN]

Synonyms

  • Avetol
  • CCRIS 487
  • Cornutamin
  • EINECS 206-835-9
  • Ergam
  • Ergate
  • Ergomar
  • Ergostat
  • Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (2:1) (salt)
  • Ergotamine bitartrate
  • Ergotamine hemitartrate
  • Ergotamine tartrate
  • Ergotamine tartrate (2:1) (salt)
  • Ergotamine tartrate (VAN)
  • Ergotamine, tartrate (2:1)
  • Ergotartrate
  • ETIN
  • Exmigra
  • Femergin
  • Gotamine tartrate
  • Gynergen
  • Lingraine
  • Lingran
  • Medihaler ergotamine
  • Migretamine
  • Neo-ergotin
  • NSC 41869
  • Rigetamin
  • Secagyn
  • Secupan
  • UNII-MRU5XH3B48
  • Wigrettes

Systematic Names

  • Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1) (salt)
  • Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5alpha)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1)
  • Ergotamine tartrate
  • Ergotamine, tartrate (2:1) (salt) (8CI)

Superlist Name

  • Ergotamine tartrate

Mixture Name

  • Cafergot

Registry Numbers

CAS Registry Number

  • 379-79-3

FDA UNII

  • MRU5XH3B48

Other Registry Number

  • 98260-31-2

Related Registry Number

  • 113-15-5 (Parent)

System Generated Number

  • 0000379793

Molecular Formulas

Molecular Formula

  • C33-H35-N5-O5.1/2C4-H6-O6

Molecular Formula Fragments

  • C33-H35-N5-O5
  • C4-H6-O6
  • COMPONENT

Structure Descriptors

InChI

1S/2C33H35N5O5.C4H6O6/c2*1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32;5-1(3(7)8)2(6)4(9)10/h2*3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39);1-2,5-6H,(H,7,8)(H,9,10)/t2*21-,25-,26+,27+,32-,33+;1-,2-/m111/s1

InChIKey

CJMJLDQKTOJACI-BGQAIRJTSA-N

Smiles

CN1C[C@@H](C=C2[C@H]1Cc3c[nH]c4cccc2c34)C(=O)N[C@]5(C)O[C@@]6(O)[C@@H]7CCCN7C(=O)[C@H](Cc8ccccc8)N6C5=O.CN9C[C@@H](C=C%10[C@H]9Cc%11c[nH]c%12cccc%10c%11%12)C(=O)N[C@]%13(C)O[C@@]%14(O)[C@@H]%15CCCN%15C(=O)[C@H](Cc%16ccccc%16)N%14C%13=O.O[C@H]([C@@H](O)C(=O)O)C(=O)O

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
cat LD50 subcutaneous 11mg/kg (11mg/kg)   Bulletin der Schweizerischen Akademie der Medizinischen Wissenschaften. Vol. 2, Pg. 1, 1946/1947.
human TDLo oral 3700ug/kg/26W (3.7mg/kg) GASTROINTESTINAL: NAUSEA OR VOMITING

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS"
Headache. Vol. 18, Pg. 95, 1978.
man TDLo oral 214ug/kg (0.214mg/kg) BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) Muenchener Medicinische Wochenschrift. Vol. 75, Pg. 736, 1928.
mouse LD50 intraperitoneal 412mg/kg (412mg/kg)   British UK Patent Application. Vol. #2025960,
mouse LD50 intravenous 62mg/kg (62mg/kg)   Bulletin der Schweizerischen Akademie der Medizinischen Wissenschaften. Vol. 2, Pg. 1, 1946/1947.
mouse LDLo oral 300mg/kg (300mg/kg)   Teratology, The International Journal of Abnormal Development. Vol. 7, Pg. 227, 1973.
rabbit LDLo oral 1mg/kg (1mg/kg)   Teratology, The International Journal of Abnormal Development. Vol. 7, Pg. 227, 1973.
rat LD50 intravenous 80mg/kg (80mg/kg)   Bulletin der Schweizerischen Akademie der Medizinischen Wissenschaften. Vol. 2, Pg. 1, 1946/1947.
rat LDLo oral 1mg/kg (1mg/kg)   Teratology, The International Journal of Abnormal Development. Vol. 7, Pg. 227, 1973.
women TDLo oral 700ug/kg/14D- (0.7mg/kg) VASCULAR: REGIONAL OR GENERAL ARTERIOLAR CONSTRICTION

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
British Journal of Clinical Practice. Vol. 49, Pg. 214, 1995.
women TDLo oral 11mg/kg/13W-I (11mg/kg) VASCULAR: BP ELEVATION NOT CHARACTERIZED IN AUTONOMIC SECTION Postgraduate Medical Journal. Vol. 61, Pg. 461, 1985.